Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?

The European respiratory journal·2026
Same author

Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial.

American journal of respiratory and critical care medicine·2026
Same author

Pleural fluid neutrophil extracellular traps are associated with disease severity and risk of one-year mortality in pleural infection. An observational, international, multicohort study (TORPIDS-3).

The European respiratory journal·2026
Same author

Find your career: the ERS "My Career Path" series.

Breathe (Sheffield, England)·2026
Same author

The European Respiratory Society guideline for management of adult bronchiectasis: clinical summary.

Breathe (Sheffield, England)·2026
Same author

Multidrug-resistant <i>Haemophilus influenzae</i> cluster of severe asthma from sputum bacteriome-resistome.

ERJ open research·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Apr 10, 2026

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

5.9K

Targeting Inflammation in Bronchiectasis.

Micheál Mac Aogáin1,2, Amy Gilmour3, James D Chalmers3,4

  • 1Department of Biochemistry, St. James's Hospital, Dublin, Ireland.

Drugs
|April 9, 2026
PubMed
Summary
This summary is machine-generated.

Bronchiectasis involves chronic infection and inflammation. Targeting neutrophil-driven inflammation and understanding diverse microbial roles are key for new therapies, moving beyond just infection control.

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.3K
A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

12.2K

Related Experiment Videos

Last Updated: Apr 10, 2026

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

5.9K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

8.3K
A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

12.2K

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Microbiology

Background:

  • Bronchiectasis is characterized by chronic infection, inflammation, and impaired mucociliary clearance, leading to lung injury.
  • Neutrophil-driven inflammation significantly impacts disease severity, exacerbations, and quality of life in bronchiectasis.
  • Recent research reveals distinct inflammatory endotypes influenced by microbial species, immune signaling, and mucosal immunity failures.

Purpose of the Study:

  • To synthesize recent mechanistic and clinical insights into airway inflammation in bronchiectasis.
  • To propose an integrated framework for understanding and targeting inflammation.
  • To highlight the need for improved endotyping and biomarker-guided patient selection for novel therapies.

Main Methods:

  • Review and synthesis of current mechanistic and clinical research on bronchiectasis inflammation.
  • Analysis of emerging roles of microbial interactions, fungi, pathobionts, and the microbiome.
  • Evaluation of current and emerging anti-inflammatory therapeutic strategies.

Main Results:

  • Inflammatory endotypes are defined by microbial composition, immune receptor activation, and cytokine networks.
  • Viral-bacterial interactions and the broader microbiome challenge the infection-only paradigm.
  • Emerging anti-inflammatory strategies show promise, contrasting with mixed results from antibacterial trials.

Conclusions:

  • Understanding the heterogeneity of microbiome and host immune signaling is crucial for effective treatment.
  • Anti-inflammatory approaches, guided by better endotyping and biomarkers, are essential for managing bronchiectasis.
  • An integrated framework is needed to effectively target airway inflammation in bronchiectasis.